• Publications
  • Influence
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
The data show letrozole 2.5 mg once daily to be more effective and better tolerated than MA in the treatment of postmenopausal women with advanced breast cancer previously treated with antiestrogens. Expand
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.
The results demonstrate that the aggressive tumor behavior associated with a high-energy diet has similar effects on this signaling pathway and suggests a potential role for this agent in the management of a metabolically defined subset of colon cancers. Expand
Epstein‐barr virus related lymphoepithelioma‐like carcinoma of lung
A malignant neoplasm localized to the lung is reported in a rather unusual host: a 40‐year‐old female, nonsmoker, of South‐East Asiatic origin, who might widen the spectrum of EBV‐associated neoplasia, by inclusion of lower respiratory tract as a target organ. Expand
Systemic cancer therapy: achievements and challenges that lie ahead
This review series begins by describing some of the major advances made in systemic cancer therapy along with some of their known side-effects and makes an attempt to describe the future of systemic cancer Therapy. Expand
Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia
The findings provide the first essential information for the development of a VSV-based treatment for ATL, emphasizing the concept that VSV targets genetic defects unique to tumor cells to facilitate its replication. Expand
Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond
Many current chemotherapies function by damaging genomic DNA in rapidly dividing cells ultimately leading to cell death. This therapeutic approach differentially targets cancer cells that generallyExpand
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
The combination of PLD and trastuzumab is a well tolerated and active regimen in HER-2-positive MBC and cardiotoxicity was observed, but limited to asymptomatic declines in LVEF. Expand
Xenografts of Human Hepatocellular Carcinoma: A Useful Model for Testing Drugs
Hepatocellular carcinoma xenografts are powerful tools for screening drugs and SarCNU may be useful in the treatment of this fatal disease. Expand
Chlorambucil Cytotoxicity in Malignant B Lymphocytes Is Synergistically Increased by 2-(Morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-Mediated Inhibition of DNA Double-Strand Break Repair via
Results indicate that in a CLL cell line and in primary CLL-lymphocytes, chlorambucil plus NU7026 has synergistic cytotoxic activity at nontoxic doses of NU 7026, suggesting that the synergy of the combination is mediated by N U7026 inhibition of DNA-PK with subsequent inhibition of DSB repair. Expand
A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer
ZD1839, when given at 750 mg/day to patients with pre-treated metastatic colorectal cancer, does not result in significant tumor regression. Expand